Completed OBSERVATIONAL NCT01344226

Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery

Clinical Outcomes and Evaluation of Lotemax (Loteprednol Ophthalmic Solution ) 0.5% QID for Treatment of Ocular Inflammation Associated With Cataract Surgery

Sponsor: Toyos Clinic

Conditions Inflammation Pseudophakia

Interventions loteprednol 0.5% ophthalmic solution

Updated 8 times since 2017 Last updated: Jan 4, 2018 Started: Apr 30, 2011 Primary completion: Sep 30, 2013 Completion: Sep 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Inflammation and Pseudophakia, this trial is completed. The trial is conducted by Toyos Clinic and has accumulated 8 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2021 — Jul 2024 [monthly]

Completed
Jan 2021 — Dec 2021 [monthly]

Completed
Nov 2018 — Jan 2021 [monthly]

Completed

Status: Unknown Status → Completed

▶ Show 3 earlier versions

Jun 2018 — Nov 2018 [monthly]

Unknown Status
Apr 2018 — Jun 2018 [monthly]

Unknown Status

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Unknown Status NA

First recorded

Apr 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Toyos Clinic

Data source: Toyos Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Independence, United States